[go: up one dir, main page]

PE20160012A1 - Tratamiento de enfermedades miopaticas y neurogenerativas por agregacion de proteina mediante administracion parenteral - Google Patents

Tratamiento de enfermedades miopaticas y neurogenerativas por agregacion de proteina mediante administracion parenteral

Info

Publication number
PE20160012A1
PE20160012A1 PE2015002367A PE2015002367A PE20160012A1 PE 20160012 A1 PE20160012 A1 PE 20160012A1 PE 2015002367 A PE2015002367 A PE 2015002367A PE 2015002367 A PE2015002367 A PE 2015002367A PE 20160012 A1 PE20160012 A1 PE 20160012A1
Authority
PE
Peru
Prior art keywords
administration
myopathic
treatment
protein
neurogenerative diseases
Prior art date
Application number
PE2015002367A
Other languages
English (en)
Inventor
Dalia Megiddo
Original Assignee
Bio Blast Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Blast Pharma Ltd filed Critical Bio Blast Pharma Ltd
Publication of PE20160012A1 publication Critical patent/PE20160012A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/04—Disaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se divulga una formulacion farmaceutica acuosa inyectable que comprende una cantidad terapeuticamente efectiva de trehalosa, donde la concentracion de trehalosa es entre 0.1% (p/v) a 50 % (p/v)
PE2015002367A 2013-05-07 2014-05-07 Tratamiento de enfermedades miopaticas y neurogenerativas por agregacion de proteina mediante administracion parenteral PE20160012A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361820278P 2013-05-07 2013-05-07

Publications (1)

Publication Number Publication Date
PE20160012A1 true PE20160012A1 (es) 2016-02-14

Family

ID=51022384

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015002367A PE20160012A1 (es) 2013-05-07 2014-05-07 Tratamiento de enfermedades miopaticas y neurogenerativas por agregacion de proteina mediante administracion parenteral

Country Status (14)

Country Link
US (4) US10493023B2 (es)
EP (2) EP4218769A3 (es)
JP (5) JP6837835B2 (es)
KR (1) KR20160009617A (es)
AU (5) AU2014264228A1 (es)
CA (2) CA2911399A1 (es)
CR (1) CR20150637A (es)
EA (1) EA201501054A1 (es)
IL (1) IL241757B (es)
MD (1) MD20150120A2 (es)
MX (1) MX2015015355A (es)
PE (1) PE20160012A1 (es)
SG (1) SG11201509030TA (es)
WO (1) WO2014181333A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9084720B2 (en) 2013-05-07 2015-07-21 BioBlast Pharma Ltd. Compositions and methods for treating oculopharyngeal muscular dystrophy
US20220288096A1 (en) * 2013-05-07 2022-09-15 Seelos Therapeutics, Inc. Compositions and methods for treating an aggregation disease or disorder
CA2911399A1 (en) 2013-05-07 2014-11-13 Bio Blast Pharma Ltd. Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose
US10736909B2 (en) 2016-02-08 2020-08-11 Junaxo, Inc. Use of trehalose for treatment of neurological diseases
MX388562B (es) 2016-04-21 2025-03-20 Baylor College Medicine Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal.
ES2938546T3 (es) 2017-08-14 2023-04-12 Prilenia Neurotherapeutics Ltd Método de tratamiento de la esclerosis lateral amiotrófica con pridopidina
US11844808B2 (en) 2018-01-16 2023-12-19 Women & Infants Hospital Of Rhode Island Methods and compositions for treating pre-eclampsia
EP4037767A1 (en) * 2019-10-01 2022-08-10 Seelos Therapeutics, Inc. Trehalose formulations and uses thereof
CA3167214A1 (en) * 2020-02-13 2021-08-19 Michal Geva Combination therapy for treating amyotrophic lateral using pridopidine and another active agent
WO2022013940A1 (ja) 2020-07-14 2022-01-20 オリンパス株式会社 嚥下検査用システム、嚥下検査方法及び嚥下検査プログラムを記録した記録媒体
CN116966192A (zh) * 2022-09-26 2023-10-31 西安文理学院 海藻糖在制备sca3疾病治疗药物中的应用
EP4626442A1 (en) * 2022-11-30 2025-10-08 Seelos Therapeutics, Inc. Trehalose for treating huntington's disease

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3782404A (en) 1972-06-14 1974-01-01 Commercial Shearing Adjustable, metered, directional flow control arrangements
JPS4950521U (es) 1972-08-14 1974-05-02
JPS516109B2 (es) 1972-12-28 1976-02-25
JPS557829Y2 (es) 1974-07-01 1980-02-21
JPS516109A (en) 1974-07-05 1976-01-19 Toshiba Tungaloy Co Ltd Aruminaatankachitan chitsukachitankeishoketsugokin
WO1997024129A1 (en) 1995-12-27 1997-07-10 Rohto Pharmaceutical Co., Ltd. Pharmaceutical composition containing trehalose
JP4033510B2 (ja) 1995-12-27 2008-01-16 ロート製薬株式会社 トレハロースを含有する眼科用医薬組成物
JP3455633B2 (ja) 1996-06-28 2003-10-14 味の素ファルマ株式会社 潰瘍性大腸炎の予防又は治療剤
US6440446B1 (en) 1998-04-22 2002-08-27 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Agent for anti-osteoporosis
US6602865B1 (en) 1998-11-16 2003-08-05 Ivax Drug Research Institute, Ltd. Pyridazino(4,5-b)(1,5)oxazepinone, -thiazepinone and -diazepinone compounds
JP2001302517A (ja) * 2000-04-24 2001-10-31 Tokyo Univ Of Pharmacy & Life Science 脳浮腫の予防治療薬
CA2355814C (en) 2000-09-14 2010-06-29 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Pharmaceutical composition for ophthalmic use
JP4754066B2 (ja) 2000-12-22 2011-08-24 株式会社林原生物化学研究所 抗関節障害剤
JP4255101B2 (ja) 2002-03-15 2009-04-15 独立行政法人理化学研究所 神経変性疾患の治療薬
WO2004060343A1 (en) * 2002-12-31 2004-07-22 Nektar Therapeutics Antibody-containing particles and compositions
JP4904811B2 (ja) 2003-02-13 2012-03-28 株式会社林原生物化学研究所 α，α−トレハロースの糖質誘導体を含有することを特徴とする皮膚外用剤
US20050215562A1 (en) * 2003-06-23 2005-09-29 Patrick Tremblay Methods for treating protein aggregation disorders
US20050100637A1 (en) 2003-11-12 2005-05-12 Robert Murray Carbohydrate and electrolyte replacement composition
US20060099567A1 (en) * 2004-04-08 2006-05-11 Biomatrica, Inc. Integration of sample storage and sample management for life science
US20060257391A1 (en) * 2005-05-11 2006-11-16 Bausch & Lomb Incorporated Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions
CA2608198A1 (en) 2005-05-13 2006-11-23 Whitehead Institute For Biomedical Research Modulators of alpha-synuclein toxicity
MY142987A (en) 2005-06-08 2011-02-14 Hayashibara Biochem Lab Solution for tissue adhesion prevention and method for tissue adhesion prevention
JP2006342108A (ja) * 2005-06-09 2006-12-21 Mitsubishi Chemicals Corp アミロスフェロイドにより発生する疾患の予防治療剤
WO2007018124A1 (ja) 2005-08-11 2007-02-15 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo コラーゲン産生増強剤とその用途
ES2480942T3 (es) 2005-11-30 2014-07-29 The Nisshin Oillio Group, Ltd. Composición de éster de ácido graso de trehalosa
JP4950521B2 (ja) 2006-03-08 2012-06-13 公益財団法人野口研究所 トレハロース誘導体とその製造法
PT2000473E (pt) 2006-03-27 2011-07-01 Otsuka Chemical Co Ltd Composto de trealose e preparação farmacêutica que contém esse composto
CN100571707C (zh) 2006-07-24 2009-12-23 凌沛学 含有海藻糖的关节腔内注射给药制剂
EP2123662B1 (en) 2007-01-31 2013-12-04 Glytech, Inc. Trehalose compound, process for production of the compound, and immuno-stimulative agent comprising the compound
CN101646442B (zh) 2007-02-23 2013-09-04 21世纪国际新技术株式会社 血管痉挛的治疗剂或预防剂
WO2008133884A2 (en) 2007-04-23 2008-11-06 Combinatorx, Incorporated Methods and compositions for the treatment of neurodegenerative disorders
EA201070544A1 (ru) * 2007-10-31 2010-12-30 Диффьюжн Фармасьютикалз Ллс Новый класс терапевтических веществ, усиливающих диффузию низкомолекулярных соединений
JP2009249292A (ja) * 2008-04-01 2009-10-29 Toray Ind Inc ポリリン酸を安定化剤とするエリスロポエチン溶液製剤
US20110142799A1 (en) * 2008-06-23 2011-06-16 President And Fellows Of Harvard College Modulation of neurodegenerative disease by modulating xbp-1 activity
KR101021078B1 (ko) * 2008-07-22 2011-03-14 포항공과대학교 산학협력단 이노시톨 또는 트리할로스 유도체 및 이를 함유하는 퇴행성뇌신경계 질환 치료용 약학 조성물
US8741871B2 (en) 2008-10-31 2014-06-03 Glytech, Inc. Trehalose compound, method for producing same, and pharmaceutical product containing the compound
US20110293605A1 (en) * 2008-11-12 2011-12-01 Hasige Sathish Antibody formulation
DK3689346T3 (da) 2008-12-10 2024-02-26 Wista Lab Ltd 3,6-disubstitueret xanthyliumsalte til behandling af tauopati
EP2248518B1 (en) 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
EP2458990B1 (en) * 2009-07-28 2016-03-30 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
JP5869882B2 (ja) 2010-03-05 2016-02-24 株式会社林原 インスリン抵抗性の予防及び／又は改善剤
KR20230159646A (ko) 2010-06-25 2023-11-21 샤이어 휴먼 지네틱 테라피즈 인크. 이듀로네이트-2-설파타제의 cns 전달을 위한 방법들 및 조성물들
CN101914118B (zh) 2010-08-06 2012-07-04 山东大学 海藻糖衍生物及其制备方法与应用
US20140066439A1 (en) * 2010-11-10 2014-03-06 Katholieke Universiteit Leuen, K.U.Leuven R&D Osteoclast activity
US9186356B2 (en) 2011-01-08 2015-11-17 Academia Sinica Methods for treating frontotemporal lobar degeneration with ubiquitinated inclusions (FTLD-U)
WO2012177778A1 (en) 2011-06-20 2012-12-27 Mount Sinai School Of Medicine Anti-tnf- therapy for the mucopolysaccharidoses and other lysosomal disorders
US8623839B2 (en) * 2011-06-30 2014-01-07 Depuy Mitek, Llc Compositions and methods for stabilized polysaccharide formulations
US20130310467A1 (en) 2012-03-06 2013-11-21 The Nisshin Oillio Group, Ltd. Trehalose fatty acid ester composition
JP5432322B2 (ja) 2012-05-08 2014-03-05 株式会社大塚製薬工場 トレハロース含有肺塞栓形成予防用哺乳動物細胞懸濁液
US20130312784A1 (en) 2012-05-24 2013-11-28 For Your Ease Only, Inc. Cosmetic organizer
US20140032304A1 (en) 2012-07-27 2014-01-30 Google Inc. Determining a correlation between presentation of a content item and a transaction by a user at a point of sale terminal
JP2014139160A (ja) 2012-12-21 2014-07-31 Masaaki Hayashibara 脳機能改善剤及び脳機能改善用食品
US20220288096A1 (en) 2013-05-07 2022-09-15 Seelos Therapeutics, Inc. Compositions and methods for treating an aggregation disease or disorder
US9084720B2 (en) 2013-05-07 2015-07-21 BioBlast Pharma Ltd. Compositions and methods for treating oculopharyngeal muscular dystrophy
CA2911399A1 (en) 2013-05-07 2014-11-13 Bio Blast Pharma Ltd. Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose
JP6130224B2 (ja) 2013-05-27 2017-05-17 公益財団法人微生物化学研究会 新規化合物レンツトレハロース、その製造方法、及びその用途、並びに、新規微生物
TWI507197B (zh) 2013-07-17 2015-11-11 Univ Nat Taiwan Normal 醫藥組成物於製備不正常多麩醯胺聚集類疾病之藥物上之用途
WO2015009961A1 (en) 2013-07-19 2015-01-22 Armagen Technologies, Inc. Compositions and methods related to structures that cross the blood brain barrier
CA2967066A1 (en) 2014-11-19 2016-05-26 Rush University Medical Center Use of cinnamic acid or sodium benzoate for treating lysosomal disorders
US20160303150A1 (en) 2015-04-16 2016-10-20 BioBlast Pharma Ltd. Deuterated trehalose formulations and uses thereof
WO2017136533A1 (en) 2016-02-03 2017-08-10 The Trustees Of The University Of Pennsylvania Methods for treating diagnosing, and monitoring treatment of mucopolysaccharidoses
MX388562B (es) 2016-04-21 2025-03-20 Baylor College Medicine Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal.
EP4037767A1 (en) 2019-10-01 2022-08-10 Seelos Therapeutics, Inc. Trehalose formulations and uses thereof

Also Published As

Publication number Publication date
AU2019204513B2 (en) 2020-09-10
HK1217300A1 (en) 2017-01-06
JP2023040211A (ja) 2023-03-22
US12239733B2 (en) 2025-03-04
AU2019204513A1 (en) 2019-07-18
EP4218769A2 (en) 2023-08-02
CA2911399A1 (en) 2014-11-13
JP2025087858A (ja) 2025-06-10
JP2021152032A (ja) 2021-09-30
EP4218769A3 (en) 2023-10-18
US20220117883A1 (en) 2022-04-21
MD20150120A2 (ro) 2016-03-31
US10869831B2 (en) 2020-12-22
US20240009113A1 (en) 2024-01-11
JP6837835B2 (ja) 2021-03-03
US10493023B2 (en) 2019-12-03
AU2025201824A1 (en) 2025-04-03
EA201501054A1 (ru) 2016-04-29
CR20150637A (es) 2016-04-05
SG11201509030TA (en) 2015-11-27
JP2016518403A (ja) 2016-06-23
CA3239805A1 (en) 2014-11-13
WO2014181333A2 (en) 2014-11-13
JP2019142907A (ja) 2019-08-29
WO2014181333A3 (en) 2015-01-08
EP2994145A2 (en) 2016-03-16
KR20160009617A (ko) 2016-01-26
AU2014264228A1 (en) 2015-11-12
AU2020277197A1 (en) 2020-12-24
AU2023200303A1 (en) 2023-02-23
MX2015015355A (es) 2016-07-18
US20190374463A1 (en) 2019-12-12
EP2994145B1 (en) 2023-01-04
IL241757B (en) 2020-05-31
US20160120798A1 (en) 2016-05-05

Similar Documents

Publication Publication Date Title
PE20160012A1 (es) Tratamiento de enfermedades miopaticas y neurogenerativas por agregacion de proteina mediante administracion parenteral
CY1124436T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια
BR112015016930A2 (pt) formulações farmacêuticas estabilizadas de análogos de insulina e/ou derivados de insulina
AR107014A1 (es) Formulación farmacéutica acuosa
BR112018075140A2 (pt) composição na forma de uma solução aquosa injetável, e, formulação de dose única a um ph de 7 a 7,8
MX375752B (es) Inhibidores de tirosina quinasa de bruton.
AR098168A1 (es) Formulación estable de insulina glulisina
MX375417B (es) Uso de ácido (r)-2-[3-[[n-(benzoxazol-2-il)-n-3-(4-metoxifenoxi)propil]aminometil]fenoxi]butírico o una sal, o solvato del mismo para el tratamiento de la esteatosis hepática no alcohólica, supresión de la deposición de grasa en el hígado, y en la reducción de células de kupffer en el hígado.
BR112015021888A8 (pt) inibidores de dna-pk, seus usos e composição farmacêutica
EA201690618A1 (ru) Ингибиторы тирозинкиназы брутона
EA201991484A1 (ru) Лекарственные формы энзалутамида
MX366317B (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
EA202090683A3 (ru) Способы и композиции для лечения рака
UA116999C2 (uk) Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить
MX2017003121A (es) Formulaciones de anticuerpos.
CL2015002835A1 (es) Nuevos derivados de piridina
UA115811C2 (uk) Стабільний розчин об'єднаних баклофену, сорбіту і налтрексону для перорального застосування
MX2015009045A (es) Composiciones y metodos para tratar el dolor severo.
MX2017008277A (es) Solucion oftalmica acuosa.
MX2015012783A (es) Administracion subcutanea de una desintegrina y metaloproteinasa con motivos tipo i de trombospondina 13 (adamts13).
EA201690323A1 (ru) Способы лечения заболеваний уха у детей
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
MX2016015211A (es) Formulaciones topicas y usos de las mismas.
EA201691860A1 (ru) Пептидный медикамент в виде сухого порошка
MX377510B (es) Uso de levocetirizina y montelukast en el tratamiento de anafilaxis.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal